Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Neurodegenerative CSF markers in genetic and sporadic PD: Classification and prediction in a longitudinal study.

Parkinsonism & related disorders - 1 Dec 2015

Brockmann Kathrin, Schulte Claudia, Deuschle Christian, Hauser Ann-Kathrin, Heger Tanja, Gasser Thomas, Maetzler Walter, Berg Daniela

Abstract excerpt

BACKGROUND: Parkinson's disease (PD) patients show a large phenotypic variability probably reflecting inter-individual pathologic heterogeneity. Next to typical Lewy-body pathology, β-amyloid (Aβ) and tau pathology have been found at autopsy and several studies have reported altered CSF levels of Aβ1-42, total-Tau (t-Tau) and phosphorylated-Tau (p-Tau). OBJECTIVES: To evaluate whether CSF levels of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amyloid beta-Peptides
Share to Cognition Disorders

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glucosylceramidase

Share to Leucine-Rich Repeat Serine-Threonine Protein Kinase-2

Share to Protein Processing, Post-Translational

Share to Regression Analysis

Share to Socioeconomic Factors

Share to tau Proteins

Source

Identifiers

PMID: 26475624
DOI: 10.1016/j.parkreldis.2015.10.008

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Neurodegenerative CSF markers in genetic and sporadic PD: Classification and prediction in a longitudinal study.PMID 26475624Read ↗

CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study.Semantic proximity Read ↗

Tau protein and beta-amyloid(1-42) CSF levels in different phenotypes of Parkinson's disease.Semantic proximity Read ↗

Cerebrospinal fluid amyloid β and tau in LRRK2 mutation carriers.Semantic proximity Read ↗

A proteogenomic view of Parkinson’s disease causality and heterogeneitySemantic proximity Read ↗

CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study.Semantic proximity Read ↗

β-Amyloid and tau biomarkers and clinical phenotype in dementia with Lewy bodies.Semantic proximity Read ↗

Discovery, validation and optimization of cerebrospinal fluid biomarkers for use in Parkinson’s diseaseSemantic proximity Read ↗

CSF biomarkers in different phenotypes of Parkinson disease.Semantic proximity Read ↗

Cognitive impairment in Glucocerebrosidase (GBA)-associated PD: Not primarily associated with cerebrospinal fluid Abeta and Tau profiles.Semantic proximity Read ↗

Cerebrospinal Fluid Biomarker Profile in TDP-43-Related Genetic Frontotemporal DementiaSemantic proximity Read ↗

High cerebrospinal tau levels are associated with the rs242557 tau gene variant and low cerebrospinal β-amyloid in Parkinson disease.Semantic proximity Read ↗

Cerebrospinal fluid amyloid-β and phenotypic heterogeneity in de novo Parkinson's disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.